Association of OSMR Gene Polymorphisms with Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients

References

• Cross, A., S. W. Edwards, R. C. Bucknall, and R. J. Moots. 2004. Secretion of oncostatin M by neutrophils in rheumatoid arthritis. Arthritis Rheumat. 50: 1430–1436
   PubMed Web of Science ®Google Scholar
• Silver, J. S., and C. A. Hunter. 2010. gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 88: 1145–1156
   PubMed Web of Science ®Google Scholar
• Nakamura, K., H. Nonaka, H. Saito, et al. 2004. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39: 635–644
   PubMed Web of Science ®Google Scholar
• Migita, K., A. Komori, T. Torigoshi, et al. 2011. CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res. Ther. 13: R72
   Web of Science ®Google Scholar
• Naka, T., and T. Kishimoto. 2002. Joint disease caused by defective gp130-mediated STAT signaling. Arthritis Res. 4: 154–156
   PubMedGoogle Scholar
• Heinrich, P. C., I. Behrmann, S. Haan, et al. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374: 1–20
   PubMed Web of Science ®Google Scholar
• Hui, W., M. Bell, and G. Carroll. 1997. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann. Rheum. Dis. 56: 184–187
   PubMed Web of Science ®Google Scholar
• Okamoto, H., M. Yamamura, Y. Morita, et al. 1997. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheumat. 40: 1096–1105
   PubMed Web of Science ®Google Scholar
• Robak, E., A. Sysa-Jedrzejowska, H. Stepien, and T. Robak. 1997. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 8: 281–286
   PubMed Web of Science ®Google Scholar
• Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356–361
   PubMed Web of Science ®Google Scholar
• Bingham, C. O., 3rd 2002. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J. Rheumatol. Suppl. 65: 3–9
   PubMedGoogle Scholar
• Brennan, F. M., A. L. Hayes, C. J. Ciesielski, et al. 2002. Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheumat. 46: 31–41
   PubMed Web of Science ®Google Scholar
• McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429–442
   PubMed Web of Science ®Google Scholar
• Radonic, A., S. Thulke, I. M. Mackay, et al. 2004. Guideline to reference gene selection for quantitative real-time PCR. Biochem. Biophys. Res. Commun. 313: 856–862
   PubMed Web of Science ®Google Scholar
• Sweeney, S. E., and G. S. Firestein. 2004. Signal transduction in rheumatoid arthritis. Curr. Opin. Rheumatol. 16: 231–237
   PubMed Web of Science ®Google Scholar
• Franceschini, F., and I. Cavazzana. 2005. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 38: 55–63
   PubMed Web of Science ®Google Scholar
• Menendez, A., J. Gomez, E. Escanlar, et al. 2013. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: diagnostic utility of their separate detection. Autoimmunity 46: 32–39
   PubMed Web of Science ®Google Scholar
• Gal, I., G. Lakos, and M. Zeher. 2000. Comparison of the anti-Ro/SSA autoantibody profile between patients with primary and secondary Sjogren's syndrome. Autoimmunity 32: 89–92
   PubMed Web of Science ®Google Scholar
• Xue, D., H. Shi, J. D. Smith, et al. 2003. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc. Natl. Acad. Sci. USA 100: 7503–7508
   PubMed Web of Science ®Google Scholar
• Hintzen, C., S. Quaiser, T. Pap, et al. 2009. Induction of CCL13 expression in synovial fibroblasts highlights a significant role of oncostatin M in rheumatoid arthritis. Arthritis Rheumat. 60: 1932–1943
   PubMed Web of Science ®Google Scholar
• Zhang, Q., P. Putheti, Q. Zhou, et al. 2008. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 19: 347–356
   PubMed Web of Science ®Google Scholar
• Julia, A., J. Ballina, J. D. Canete, et al. 2008. Genome-wide association study of rheumatoid arthritis in the Spanish population: KLF12 as a risk locus for rheumatoid arthritis susceptibility. Arthritis Rheumat. 58: 2275–2286
   PubMed Web of Science ®Google Scholar
• Curk, T., G. Rot, and B. Zupan. 2011. SNPsyn: detection and exploration of SNP-SNP interactions. Nucleic Acids Res. 39: W444–W449
   Web of Science ®Google Scholar
• van der Pouw Kraan, T. C., F. A. van Gaalen, P. V. Kasperkovitz, et al. 2003. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheumat. 48: 2132–2145
   PubMed Web of Science ®Google Scholar
• Marinescu, V. D., I. S. Kohane, and A. Riva. 2005. MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinform. 6: 79
   PubMed Web of Science ®Google Scholar
• Patel, D. R. 2011. Linking interferon regulatory factors to the pathogenesis of human lupus. Transl. Res.: J. Lab. Clin. Med. 157: 323–325
   Google Scholar
• Luk, T., Z. Malam, and J. C. Marshall. 2008. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J. Leukoc. Biol. 83: 804–816
   PubMed Web of Science ®Google Scholar
• Otero, M., R. Lago, R. Gomez, et al. 2006. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65: 1198–1201
   PubMed Web of Science ®Google Scholar
• Brentano, F., O. Schorr, C. Ospelt, et al. 2007. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheumat. 56: 2829–2839
   PubMed Web of Science ®Google Scholar
• Nowell, M. A., P. J. Richards, C. A. Fielding, et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheumat. 54: 2084–2095
   PubMed Web of Science ®Google Scholar
• Harrison, P., J. J. Pointon, K. Chapman, et al. 2008. Interleukin-1 promoter region polymorphism role in rheumatoid arthritis: a meta-analysis of IL-1B-511A/G variant reveals association with rheumatoid arthritis. Rheumatology (Oxford). 47: 1768–1770
   PubMed Web of Science ®Google Scholar
• Li, R. N., Y. H. Hung, C. H. Lin, et al. 2010. Inhibitor IkappaBalpha promoter functional polymorphisms in patients with rheumatoid arthritis. J. Clin. Immunol. 30: 676–680
   PubMed Web of Science ®Google Scholar
• Lin, C. H., S. C. Wang, T. T. Ou, et al. 2008. I kappa B alpha promoter polymorphisms in patients with systemic lupus erythematosus. J. Clin. Immunol. 28: 207–213
   PubMed Web of Science ®Google Scholar